Long intergenic non-coding RNA expression signature in human breast cancer.

Zhang Y, Wagner EK, Guo X, May I, Cai Q, Zheng W, He C, Long J
Sci Rep. 2016 6: 37821

PMID: 27897201 · PMCID: PMC5126689 · DOI:10.1038/srep37821

Breast cancer is a complex disease, characterized by gene deregulation. There is less systematic investigation of the capacity of long intergenic non-coding RNAs (lincRNAs) as biomarkers associated with breast cancer pathogenesis or several clinicopathological variables including receptor status and patient survival. We designed a two-stage study, including 1,000 breast tumor RNA-seq data from The Cancer Genome Atlas (TCGA) as the discovery stage, and RNA-seq data of matched tumor and adjacent normal tissue from 50 breast cancer patients as well as 23 normal breast tissue from healthy women as the replication stage. We identified 83 lincRNAs showing the significant expression changes in breast tumors with a false discovery rate (FDR)ā€‰<ā€‰1% in the discovery dataset. Thirty-seven out of the 83 were validated in the replication dataset. Integrative genomic analyses suggested that the aberrant expression of these 37 lincRNAs was probably related with the expression alteration of several transcription factors (TFs). We observed a differential co-expression pattern between lincRNAs and their neighboring genes. We found that the expression levels of one lincRNA (RP5-1198O20 with Ensembl ID ENSG00000230615) were associated with breast cancer survival with Pā€‰<ā€‰0.05. Our study identifies a set of aberrantly expressed lincRNAs in breast cancer.

MeSH Terms (15)

Adult Aged Breast Neoplasms Case-Control Studies Female Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans MCF-7 Cells Middle Aged Protein Interaction Maps RNA, Long Noncoding Sequence Analysis, RNA Survival Analysis Transcription Factors

Connections (2)

This publication is referenced by other Labnodes entities:

Links